Selected research
Industry Research
Atovaquone and Proguanil Industry Research Report 2026
Market perspective
The global Atovaquone and Proguanil market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Atovaquone and Proguanil is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Atovaquone and Proguanil is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Atovaquone and Proguanil is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Atovaquone and Proguanil include GSK, Mylan Pharmaceuticals, Hetero and Glenmark, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Atovaquone and Proguanil market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Atovaquone and Proguanil Market by Company
GSK
Mylan Pharmaceuticals
Hetero
Glenmark
Atovaquone and Proguanil Segment by Type
250 mg/100 mg
62.5mg/25mg
Atovaquone and Proguanil Segment by Application
Adult
Paediatric
Atovaquone and Proguanil Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Atovaquone and Proguanil market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Atovaquone and Proguanil and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Atovaquone and Proguanil.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Atovaquone and Proguanil manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Atovaquone and Proguanil by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Atovaquone and Proguanil in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 250 mg/100 mg
- 62.5mg/25mg
Applications
- Adult
- Paediatric
Companies covered
- GSK
- Mylan Pharmaceuticals
- Hetero
- Glenmark
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Atovaquone and Proguanil Market Size (2021-2032)
- 2.2.2 Global Atovaquone and Proguanil Sales (2021-2032)
- 2.2.3 Global Atovaquone and Proguanil Market Average Price (2021-2032)
- 2.3 Atovaquone and Proguanil by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 250 mg/100 mg
- 2.3.3 62.5mg/25mg
- 2.4 Atovaquone and Proguanil by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adult
- 2.4.3 Paediatric
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Atovaquone and Proguanil Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Atovaquone and Proguanil Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Atovaquone and Proguanil Revenue of Manufacturers (2021-2026)
- 3.4 Global Atovaquone and Proguanil Average Price by Manufacturers (2021-2026)
- 3.5 Global Atovaquone and Proguanil Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Atovaquone and Proguanil, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Atovaquone and Proguanil, Product Type & Application
- 3.8 Global Manufacturers of Atovaquone and Proguanil, Established Date
- 3.9 Global Atovaquone and Proguanil Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Atovaquone and Proguanil Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Atovaquone and Proguanil Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Mylan Pharmaceuticals
- 4.2.1 Mylan Pharmaceuticals Company Information
- 4.2.2 Mylan Pharmaceuticals Business Overview
- 4.2.3 Mylan Pharmaceuticals Atovaquone and Proguanil Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Mylan Pharmaceuticals Atovaquone and Proguanil Product Portfolio
- 4.2.5 Mylan Pharmaceuticals Recent Developments
- 4.3 Hetero
- 4.3.1 Hetero Company Information
- 4.3.2 Hetero Business Overview
- 4.3.3 Hetero Atovaquone and Proguanil Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hetero Atovaquone and Proguanil Product Portfolio
- 4.3.5 Hetero Recent Developments
- 4.4 Glenmark
- 4.4.1 Glenmark Company Information
- 4.4.2 Glenmark Business Overview
- 4.4.3 Glenmark Atovaquone and Proguanil Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Glenmark Atovaquone and Proguanil Product Portfolio
- 4.4.5 Glenmark Recent Developments
5 Global Atovaquone and Proguanil Market Scenario by Region
- 5.1 Global Atovaquone and Proguanil Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Atovaquone and Proguanil Sales by Region: 2021-2032
- 5.2.1 Global Atovaquone and Proguanil Sales by Region: 2021-2026
- 5.2.2 Global Atovaquone and Proguanil Sales by Region: 2027-2032
- 5.3 Global Atovaquone and Proguanil Revenue by Region: 2021-2032
- 5.3.1 Global Atovaquone and Proguanil Revenue by Region: 2021-2026
- 5.3.2 Global Atovaquone and Proguanil Revenue by Region: 2027-2032
- 5.4 North America Atovaquone and Proguanil Market Facts & Figures by Country
- 5.4.1 North America Atovaquone and Proguanil Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Atovaquone and Proguanil Sales by Country (2021-2032)
- 5.4.3 North America Atovaquone and Proguanil Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Atovaquone and Proguanil Market Facts & Figures by Country
- 5.5.1 Europe Atovaquone and Proguanil Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Atovaquone and Proguanil Sales by Country (2021-2032)
- 5.5.3 Europe Atovaquone and Proguanil Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Atovaquone and Proguanil Market Facts & Figures by Country
- 5.6.1 Asia Pacific Atovaquone and Proguanil Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Atovaquone and Proguanil Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Atovaquone and Proguanil Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Atovaquone and Proguanil Market Facts & Figures by Country
- 5.7.1 South America Atovaquone and Proguanil Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Atovaquone and Proguanil Sales by Country (2021-2032)
- 5.7.3 South America Atovaquone and Proguanil Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Atovaquone and Proguanil Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Atovaquone and Proguanil Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Atovaquone and Proguanil Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Atovaquone and Proguanil Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Atovaquone and Proguanil Sales by Type (2021-2032)
- 6.1.1 Global Atovaquone and Proguanil Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Atovaquone and Proguanil Sales Market Share by Type (2021-2032)
- 6.2 Global Atovaquone and Proguanil Revenue by Type (2021-2032)
- 6.2.1 Global Atovaquone and Proguanil Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Atovaquone and Proguanil Revenue Market Share by Type (2021-2032)
- 6.3 Global Atovaquone and Proguanil Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Atovaquone and Proguanil Sales by Application (2021-2032)
- 7.1.1 Global Atovaquone and Proguanil Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Atovaquone and Proguanil Sales Market Share by Application (2021-2032)
- 7.2 Global Atovaquone and Proguanil Revenue by Application (2021-2032)
- 7.2.1 Global Atovaquone and Proguanil Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Atovaquone and Proguanil Revenue Market Share by Application (2021-2032)
- 7.3 Global Atovaquone and Proguanil Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Atovaquone and Proguanil Value Chain Analysis
- 8.1.1 Atovaquone and Proguanil Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Atovaquone and Proguanil Production Mode & Process
- 8.2 Atovaquone and Proguanil Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Atovaquone and Proguanil Distributors
- 8.2.3 Atovaquone and Proguanil Customers
9 Global Atovaquone and Proguanil Analyzing Market Dynamics
- 9.1 Atovaquone and Proguanil Industry Trends
- 9.2 Atovaquone and Proguanil Industry Drivers
- 9.3 Atovaquone and Proguanil Industry Opportunities and Challenges
- 9.4 Atovaquone and Proguanil Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst